Cancer Research UK’s Stratified Medicine Programme aims to establish a national molecular diagnostics service that delivers high-quality, cost-effective tests for patients. This programme marks the beginning of a step change in cancer treatment. As a matter of routine, it will obtain patients’ consent for their genetic, treatment and outcomes data to be used in the development of new personalised cancer treatments.
Cancer Research UK asked PA to identify the minimum standards required to deliver phase one of the programme, which involves the collection and genetic testing of 9,000 tissue samples.
PA provided management and IT consultancy to help determine key processes and infrastructure. We also worked with Cancer Research UK to coordinate discussions between clinicians and researchers to establish the minimum standards required to deliver the programme. The programme has secured funding from the UK government’s Technology Strategy Board, Pfizer and AstraZeneca. This first pilot phase will establish a model of the processes required to deliver the programme in six major cancer types.
“We want all cancer patients in the UK to have access to targeted cancer treatments as soon as they become available, and for research into which treatments are best suited to an individual patient’s cancer to be hard-wired into routine cancer care.”
Director of Cancer Research
UK’s Stratified Medicine Programme